Molecure (MOC) Q2 2024 earnings summary

Executive summary

• Molecure S.A. focuses on developing small-molecule drugs for high unmet clinical needs, including cancer and respiratory diseases, with a business model reliant on long-term R&D and delayed revenue from commercialization or licensing of research outcomes.

• The company reported a net loss of PLN 14.6 million for H1 2024, consistent with its R&D-driven model and the absence of significant product sales.

• No material uncertainty regarding going concern was identified; the company maintains sufficient liquidity and continues its research programs.

Financial highlights

• Total operating revenue for H1 2024 was PLN 305,048, down from PLN 1,799,939 in H1 2023, mainly from government grants.

• Operating expenses decreased to PLN 15.4 million from PLN 17.1 million year-over-year.

• Net loss for H1 2024 was PLN 14.6 million, compared to a net loss of PLN 12.9 million in H1 2023.

• Cash and equivalents at June 30, 2024, stood at PLN 37.8 million, down from PLN 64.0 million at year-end 2023.

• Basic and diluted loss per share was PLN (0.87) for H1 2024, compared to PLN (0.77) for H1 2023.

Outlook and guidance

• Management expects continued losses in the near term due to the long R&D cycle, with revenues anticipated only after successful commercialization or licensing of drug candidates.

• The company is well-capitalized to continue its research and development activities and has secured public funding for ongoing projects.